Ziopharm Oncology to Present at the Rodman & Renshaw Annual Global Investment Conference NYC

NEW YORK--(BUSINESS WIRE)-- Press Kit Materials are Available at: http://www.tradeshownews.com/events/Rodman-Renshaw-Annual-Global-Investment-Conference-NYC/ziopharm/

Company:   Ziopharm Oncology
Event: Rodman & Renshaw Annual Global Investment Conference NYC
Sep 13 - 15, 2010
New York, NY, US
Web:

http://www.ziopharm.com

About Ziopharm Oncology

ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse, portfolio of cancer drugs. Our principal focus is on the development of proprietary small molecule drug candidates that work on validated targets. The goal is to develop intravenous ("IV") and/or oral forms of administration. We believe this strategy will result in lower-risk and lower-cost development programs with product candidates having a low cost of manufacturing to address changing reimbursement requirements around the world.



CONTACT:

Ziopharm Oncology
Lori Ann Cafarella, 646-214-0702
[email protected]
or
Cathy Brown, 617-259-1970
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Other Health  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.